Greenow, Kirsty Rhian and Smalley, Matthew John  ORCID: https://orcid.org/0000-0001-9540-1146
2015.
Overview of genetically engineered mouse models of breast cancer used in translational biology and drug development.
Current Protocols in Pharmacology
70
(1)
, 70:14.36.1-14.36.14..
10.1002/0471141755.ph1436s70
|
Abstract
Breast cancer is a heterogeneous condition with no single standard of treatment and no definitive method for determining whether a tumor will respond to therapy. The development of murine models that faithfully mimic specific human breast cancer subtypes is critical for the development of patient-specific treatments. While the artificial nature of traditional in vivo xenograft models used to characterize novel anticancer treatments has limited clinical predictive value, the development of genetically engineered mouse models (GEMMs) makes it possible to study the therapeutic responses in an intact microenvironment. GEMMs have proven to be an experimentally tractable platform for evaluating the efficacy of novel therapeutic combinations and for defining the mechanisms of acquired resistance. Described in this overview are several of the more popular breast cancer GEMMs, including details on their value in elucidating the molecular mechanisms of this disorder.
| Item Type: | Article |
|---|---|
| Date Type: | Publication |
| Status: | In Press |
| Schools: | Biosciences European Cancer Stem Cell Research Institute (ECSCRI) |
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology |
| Uncontrolled Keywords: | Breast cancer; mouse models; luminal; HER2; triple negative |
| Publisher: | Wiley-Blackwell |
| Date of Acceptance: | 2015 |
| Last Modified: | 22 Jun 2023 10:00 |
| URI: | https://orca.cardiff.ac.uk/id/eprint/87672 |
Citation Data
Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
 |
Edit Item |
Altmetric
Altmetric
Cardiff University Information Services